IA
MNPR icon

IFP Advisors’s Monopar Therapeutics MNPR Stock Holding History

IFP Advisors’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-100
Closed -$13K – 4737
2022
Q3 		$13K Hold
100
– – ﹤0.01% 3456
2022
Q2 		$13K Hold
100
– – ﹤0.01% 3202
2022
Q1 		$13K Buy
+100
New +$1.48K ﹤0.01% 3202

Other funds holding MNPR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
RRCM
Rappaport Reiches Capital Management Skokie`, Illinois $400M AUM 7.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
PWS
Paragon Wealth Strategies Jacksonville, Florida $363M AUM 24.36% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

IFP Advisors's MNPR Position: Q4 2022 in Review

IFP Advisors sold out of Monopar Therapeutics (MNPR) in Q4 2022, closing a stake of 100 shares — an estimated $13K sold.

IFP Advisors first reported a position in MNPR in Q1 2022 and held it in 3 quarters. The position peaked at $13K in Q3 2022. 10 funds tracked by Wall St. Rank hold MNPR as of Q4 2022.

  • IFP Advisors reported no remaining Monopar Therapeutics position as of Q4 2022 after selling out during the quarter.
  • IFP Advisors sold 100 Monopar Therapeutics shares in Q4 2022, an estimated $13K.
  • IFP Advisors first reported a position in Monopar Therapeutics in Q1 2022 and held it in 3 quarters.
  • IFP Advisors's Monopar Therapeutics position peaked at $13K in Q3 2022.
  • 10 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q4 2022.

Based on IFP Advisors's 13F filing for Q4 2022, filed 7 Feb 2023.